Madrigal Pharmaceuticals Inc (MDGL)
283.03
+12.66
(+4.68%)
USD |
NASDAQ |
Mar 18, 16:00
274.50
-8.53
(-3.01%)
After-Hours: 05:31
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 5.632B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 12.94% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 802.82 |
Price to Book Value | 13.89 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 82.20% |
Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
URL | http://www.madrigalpharma.com |
Investor Relations URL | https://ir.madrigalpharma.com/ |
HQ State/Province | Pennsylvania |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
URL | http://www.madrigalpharma.com |
Investor Relations URL | https://ir.madrigalpharma.com/ |
HQ State/Province | Pennsylvania |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |